New research reveals that people who come off new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Research printed in a major medical journal points out that while obese people can lose a large proportion of their body weight while using the jabs, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"Individuals purchasing such drugs must be cognizant of the potential of rapid weight regain when the treatment is stopped," stated researcher Dr. Susan Jebb.
That rate of regain implies a reversion to original mass within about one and a half years.
Analyzing Approaches
The research, which examined 37 of trials involving thousands of patients, contrasted the outcomes of the injectable medications with older methods.
The team point out that individuals who shed pounds through diet and exercise typically have a slower creep back—perhaps 0.1 kg a month—after stopping.
Explaining the Quick Rebound
Doctors propose the way of the jabs explains the accelerated rebound.
These medications mimic a natural hormone called glucagon-like peptide-1, which controls appetite.
"Long-term administration of GLP-1 levels far above than normal could lead to the system to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication results in hunger is no longer kept in check, making binge eating far more likely."
An Ongoing Issue?
The NHS advise the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians say that, considering the significant potential of relapse, the treatment is often long-term.
This opinion is supported by drug manufacturers, who say that the findings "underscore the long-term character of excess weight," comparing it to managing conditions like hypertension.
Patient Accounts
Individuals who have discontinued the jabs report a intense resurgence of hunger.
"It felt as if a trigger flipping and I was suddenly extremely hungry," said a patient.
The struggle is exacerbated if individuals have not developed lasting dietary or behavioural changes during therapy.
Growing Adoption
Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is more common among females than men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while these medications are potent tools for shedding pounds, they are not a permanent cure and lasting health benefits hinges on combined lifestyle support.
